An inspection outcome, reported abroad
A regulatory observation in an export market is public, technical and immediately reportable. It reaches investors and domestic media on the same day, usually before the internal briefing is written.
IndustriesPharma & Life Sciences
A regulator's letter in one market is a headline in another.
Pharmaceutical reputation moves across borders faster than it moves across departments. Brillaince reads inspection outcomes, recall notices and trial coverage in the markets they happen in, and connects them to the brand story at home.
One engineInspection outcomesRecalls and qualityClinical trial resultsDrug pricing and accessPatent and litigationManufacturing and supplyRegulatory approvalsAdverse event reporting
- Inspection outcomes
- Recalls and quality
- Clinical trial results
- Drug pricing and access
- Patent and litigation
- Manufacturing and supply
- Regulatory approvals
- Adverse event reporting
- Prescriber and physician sentiment
- Export market actions
- Counterfeit medicines
- Public health narrative
- + your own
5,000+Press sources, global and Indian
2 hoursPress refresh cadence
40+Languages, read natively
What actually goes wrong in pharma & life sciences.
Not a generic risk list. These are the four shapes this category's bad weeks reliably take.
A recall that becomes a safety story
A quality recall is a procedural event until it is reported as a patient-safety event. The framing is set by whoever explains it first, and that is rarely the manufacturer.
What a model tells a patient about your drug
Safety, side effect and alternative questions increasingly get an assistant's answer. For a prescription product that answer influences adherence and demand, and almost nobody is reading it.
Pricing and access as a political story
Drug pricing coverage is moral and political rather than commercial, and a company named in it is rarely given room for a commercial explanation.
The order matters more than the list.
Every category has a channel that goes first. Watching them in the wrong order is how a story arrives as a phone call.
- PressUsually firstRegulatory and business coverage in every market you manufacture for or sell in, plus the trade press that reports inspection outcomes first.
- AI answersDrug safety, side effect and alternative answers, checked daily, increasingly the first source a patient consults.
- Social platformsPatient communities, prescriber conversation and the adverse-event reports that appear publicly before they appear formally.
- YouTubePhysician and patient-education content that shapes prescribing confidence and patient adherence.
Calibrated to the calendar
Inspection and approval cycles concentrate regulatory news, and trial readout windows concentrate the scientific coverage that shapes prescriber and investor sentiment together.
- 1FebInspection cycle
- 2JunTrial readouts
- 3OctResults & approvals
Thresholds move with it. A spike in your loud month is judged against your loud month, not against a flat annual average.
It was public for six hours before anyone here mentioned it.
In pharma the gap between publication in one market and coverage in another is the only preparation window you get. It is usually wasted because nobody is watching the first market.
1 / 5
- Hour 0
Published in the export market
Caught from international sources at publication and mapped to your manufacturing and quality topics, not waiting for a domestic pickup.
- Hour 2
Investor conversation starts
Investor and analyst commentary begins moving before any domestic outlet has written a word. Tracked separately from consumer conversation.
- Hour 4
Technical facts assembled
What was observed, what classification it carries and what it does not mean are separated, because the commonest failure here is a response that over-concedes.
- Hour 6
One response, several registers
A technically accurate statement, an investor-facing version and a domestic press line, all built from the same set of facts.
- Day 2
Where it landed
Which markets and desks carried it, in which framing, recorded rather than summarised from memory.
The stories this category keeps writing.
Detection is tuned against patterns, not keywords. These are the ones that matter here.
An inspection observation at a manufacturing site is published and picked up by the domestic business press the same day.
Caught by Press intelligence, global sourcesA batch recall is reported as a patient-safety story rather than as a quality procedure.
Caught by Crisis detection on framingAsked about side effects, a model repeats an out-of-date safety concern about your product.
Caught by AI reputation, checked dailyPatients discuss an adverse effect pattern publicly before it appears in formal reporting.
Caught by Social listening on topicThese are story patterns we tune this category's detection against, written by us. They are not real headlines, and they name no real company.
Which parts of the platform lead here.
Everything is included on every plan. This is the order this category leans on them in.
01Press Intelligence5,000+ sources across India and internationally, swept every 2 hours, read natively in 40+ languages including 12 Indian ones.02AI ReputationDaily tracking of the real questions your buyers ask ChatGPT, Gemini, Claude, Perplexity and Google's AI Overviews: how you're described, whether the claims are true, and whether you get recommended or a competitor does.03Crisis DetectionSpikes measured against your brand's real history, severity that escalates only when a second signal agrees, and a brief that states plainly what is known and what isn't yet.04Market IntelligenceNarrative tracking for your brand, every tracked competitor and the category itself, plus the executives your reputation rides on and the share-price context around all of it.05Content StudioStatements, rebuttals, pitches and the corrective content that reshapes what AI reads about you, drafted from the live data behind the alert instead of a blank page, in the language the story broke in.06ReportsWeekly, monthly or on-demand PDFs across any date range, covering every channel, with the same reliability rules that apply on screen.
With and without Brillaince, in this category.
Without BrillainceWith Brillaince
An overseas inspection outcomeLearned from domestic coverageCaught at publication, in that market
Investor versus consumer reactionBlended into one numberTracked as separate conversations
Recall framingSet by whoever writes firstTracked on framing from hour one
AI drug safety answersUnmonitoredChecked daily, outdated claims flagged
Patient community signalsInvisible until formal reportingVisible as a public pattern
Also in Health, Education & Media
About pharma & life sciences.
The three we are asked most in this category.
Do you provide medical or regulatory advice?
No. We track coverage, conversation and what AI models say. Clinical, regulatory and legal judgement stays with your own teams and advisers.
Do you cover export market regulators?
Yes, as press sources across North America, Europe, Asia-Pacific, the Middle East, Africa and India. In this category the first market to publish is rarely the home one.
Can you track adverse-event conversation?
Public patient conversation is tracked as a topic, which can surface a pattern earlier than formal channels. It complements pharmacovigilance; it does not replace it, and we are explicit about that distinction.
Calibrated to your category, from day one.
5,000+ press sources, 40+ languages and a workspace tuned to pharma & life sciences before your first login.
Book a Demo